Compare Dishman Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs TORRENT PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA TORRENT PHARMA DISHMAN PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 25.1 37.0 67.8% View Chart
P/BV x 3.3 9.4 35.7% View Chart
Dividend Yield % 0.7 0.6 102.2%  

Financials

 DISHMAN PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
TORRENT PHARMA
Mar-19
DISHMAN PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,964 19.1%   
Low Rs1291,245 10.4%   
Sales per share (Unadj.) Rs197.8453.4 43.6%  
Earnings per share (Unadj.) Rs21.225.8 82.2%  
Cash flow per share (Unadj.) Rs34.762.3 55.7%  
Dividends per share (Unadj.) Rs2.0017.00 11.8%  
Dividend yield (eoy) %0.81.1 75.0%  
Book value per share (Unadj.) Rs179.9279.2 64.4%  
Shares outstanding (eoy) m80.69169.22 47.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.5 36.0%   
Avg P/E ratio x11.962.2 19.1%  
P/CF ratio (eoy) x7.225.8 28.1%  
Price / Book Value ratio x1.45.7 24.3%  
Dividend payout %9.465.9 14.3%   
Avg Mkt Cap Rs m20,306271,513 7.5%   
No. of employees `0000.813.6 6.1%   
Total wages/salary Rs m5,35514,038 38.1%   
Avg. sales/employee Rs Th19,252.75,642.6 341.2%   
Avg. wages/employee Rs Th6,459.51,032.4 625.7%   
Avg. net profit/employee Rs Th2,064.1320.9 643.3%   
INCOME DATA
Net Sales Rs m15,96176,728 20.8%  
Other income Rs m265571 46.5%   
Total revenues Rs m16,22677,299 21.0%   
Gross profit Rs m4,10319,831 20.7%  
Depreciation Rs m1,0916,177 17.7%   
Interest Rs m9445,038 18.7%   
Profit before tax Rs m2,3349,187 25.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m6241,254 49.7%   
Profit after tax Rs m1,7114,363 39.2%  
Gross profit margin %25.725.8 99.5%  
Effective tax rate %26.713.6 195.8%   
Net profit margin %10.75.7 188.5%  
BALANCE SHEET DATA
Current assets Rs m11,01850,375 21.9%   
Current liabilities Rs m9,51751,653 18.4%   
Net working cap to sales %9.4-1.7 -564.7%  
Current ratio x1.21.0 118.7%  
Inventory Days Days11092 120.0%  
Debtors Days Days3568 51.0%  
Net fixed assets Rs m16,30483,648 19.5%   
Share capital Rs m161846 19.1%   
"Free" reserves Rs m12,90746,397 27.8%   
Net worth Rs m14,51647,244 30.7%   
Long term debt Rs m4,18939,129 10.7%   
Total assets Rs m29,805141,209 21.1%  
Interest coverage x3.52.8 122.9%   
Debt to equity ratio x0.30.8 34.8%  
Sales to assets ratio x0.50.5 98.6%   
Return on assets %8.96.7 133.8%  
Return on equity %11.89.2 127.6%  
Return on capital %17.512.3 142.1%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95222,103 22.4%   
Fx outflow Rs m6975,522 12.6%   
Net fx Rs m4,25516,581 25.7%   
CASH FLOW
From Operations Rs m2,78617,981 15.5%  
From Investments Rs m-1,529-2,413 63.4%  
From Financial Activity Rs m-941-13,145 7.2%  
Net Cashflow Rs m3162,380 13.3%  

Share Holding

Indian Promoters % 61.4 71.5 85.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 7.0 52.7%  
FIIs % 12.7 12.6 100.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 8.8 251.1%  
Shareholders   46,261 26,511 174.5%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   JUBILANT PHARMOVA   PANACEA BIOTECH  GLENMARK PHARMA  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare DISHMAN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS